MedTrace Logo

Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)

NCT00143975 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2010-08-12

No results posted yet for this study

Summary

GO-A-HAM:

Gemtuzumab Ozogamicin 3g/m² day 1 Cytarabine 3g/m² bid days 1-3 Mitoxantrone 12mg/m² days 2,3 All-trans Retinoic acid 45mg/m² days 4-6 and 15 mg/m² days 7-28

Conditions

  • Leukemia, Myeloid, Acute

Interventions

DRUG

Cytarabine

3 g/m2 bid. i.v day 1-3

DRUG

Mitoxantrone

12 mg/m2 i.v. day 2 and 3

DRUG

Gemtuzumab Ozogamicin

3mg/m² i.v. day 1

DRUG

All-trans-Retinoid Acid

45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28

Sponsors & Collaborators

  • University of Ulm

    lead OTHER

Principal Investigators

  • Richard F Schlenk, Dr. med. · University of Ulm / Department of Internal Medicine III

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2007-07-31
Completion
2009-06-30

Countries

  • Austria
  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00143975 on ClinicalTrials.gov